{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zalifrelimab",
    "query": {
      "intervention": "Zalifrelimab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T09:24:32.288Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05375903",
      "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer",
        "NMIBC",
        "Carcinoma in Situ of Bladder",
        "Bladder Cancer",
        "Urothelial Carcinoma Bladder",
        "Urothelial Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "UGN-301",
          "type": "DRUG"
        },
        {
          "name": "UGN-201",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-06-01",
      "completion_date": "2026-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375903"
    },
    {
      "nct_id": "NCT06782555",
      "title": "A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Evofosfamide",
          "type": "DRUG"
        },
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2025-01-08",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-21",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06782555"
    },
    {
      "nct_id": "NCT02694822",
      "title": "AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Cancers",
        "Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies"
      ],
      "interventions": [
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2016-04",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694822"
    },
    {
      "nct_id": "NCT05572970",
      "title": "Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Newport Beach, California + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05572970"
    },
    {
      "nct_id": "NCT03495882",
      "title": "A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2017-12-18",
      "completion_date": "2022-07-15",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 13,
      "location_summary": "Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03495882"
    },
    {
      "nct_id": "NCT04028063",
      "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Soft Tissue Sarcoma",
        "Advanced Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Botensilimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-01-28",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04028063"
    },
    {
      "nct_id": "NCT04943848",
      "title": "rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "rHSC-DIPGVax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Months to 18 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-01-10",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-05T09:24:32.288Z",
      "location_count": 3,
      "location_summary": "Orange, California • Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04943848"
    }
  ]
}